A randomized trial assessing the clinical efficacy and microbial eradication of 1% azithromycin ophthalmic solution vs tobramycin in adult and pediatric subjects with bacterial conjunctivitis

(3851) Views  (597) Full article downloads

Authors: Mark Abelson, Eugene Protzko, Aron Shapiro, Ana Garces-Soldana, Lyle Bowman, 1% azithromycin in DuraSite Clinical Study Group

Published Date October 2007 Volume 2007:1(2) Pages 177 - 182

DOI: http://dx.doi.org/10.2147/OPTH.S

Mark Abelson^1,2, Eugene Protzko^3,4, Aron Shapiro¹, Ana Garces-Soldana^5,a, Lyle Bowman⁵, 1% azithromycin in DuraSite Clinical Study Group

¹Ophthalmic Research Associates, North Andover, MA, USA; ²Ophthalmology, Schepens Eye Research Institute and Harvard Medical School, Boston, MA, USA; ³Ophthalmology, Seidenberg Protzko Eye Associate, Havre de Grace, MA, USA; ⁴Ophthalmology, University of Maryland School of Medicine, Baltimore, MA, USA; ⁵InSite Vision, Alameda, CA, USA; ^aNow at Amgen Pharmaceuticals

Objective: The study was designed to evaluate the efficacy of an ophthalmic formulation of 1% azithromycin in DuraSite^® (AzaSite™, InSite Vision, Alameda CA, USA) and demonstrate equivalence with 0.3% tobramycin ophthalmic solution, USP, for the treatment of bacterial conjunctivitis as defined by the resolution of clinical signs and the eradication of pathogens.

Design: Prospective, randomized, active-controlled, double-masked, phase 3 trial conducted at 47 US sites between 6 August 2004 and 6 October 2005.

Participants: Subjects aged 1 year or older with diagnosis of acute bacterial conjunctivitis.

Methods: Bacteriologically confirmed participants received either 1% azithromycin in Dura-Site (n = 159) or tobramycin (n = 157). Masked study medications were dosed 4 times a day for 5 days. Participants in the 1% azithromycin in DuraSite group were dosed twice a day with active drug on days 1 and 2 and once daily on days 3 through 5. The other doses were vehicle. Clinical signs and bacterial cultures were evaluated at visit 3 (day 6 + 1).

Results: Clinical resolution was observed in 79.9% of participants in the 1% azithromycin in DuraSite group, as compared with 78.3% of those in the tobramycin group (95% CI: –7.4–10.5). Bacterial eradication was 88.1% in the 1% azithromycin in DuraSite group vs 94.3% in the tobramycin group (95% CI: –12.4–0.0). Analyses of resistance confirmed that 1% azithromycin in DuraSite eradicated Staphylococci and Streptococci strains that are commonly resistant to azithromycin, erythromycin, and fluoroquinolones.

Conclusions: The efficacy of 1% azithromycin in DuraSite and tobramycin are equivalent; however, this formulation of azithromycin also permits effective dosing intervals of twice a day on days 1 and 2 followed by once daily on the last 3 days of therapy, for a total of 65% fewer doses. In vitro, the killing spectrum of 1% azithromycin in DuraSite appears to be enhanced relative to 1% azithromycin without DuraSite.

Keywords: azithromycin, bacterial conjunctivitis, tobramycin, ophthalmic solution

Readers of this article also read: